Curated News
By: NewsRamp Editorial Staff
April 15, 2025
Nutriband Innovates to Enhance Safety of Transdermal Drugs with AVERSA Technology
TLDR
- Nutriband's AVERSA technology enhances drug safety, offering a competitive advantage in the transdermal pharmaceutical market.
- AVERSA technology integrates aversive agents into transdermal patches to prevent drug abuse and misuse, safeguarding patient access.
- Nutriband's AVERSA technology promotes safe drug usage, improving patient care and reducing the risk of substance abuse.
- Nutriband secures patents globally for AVERSA technology, partnering with Kindeva Drug Delivery to advance abuse-deterrent fentanyl patches.
Impact - Why it Matters
This news highlights the advancements in pharmaceutical technology to address the abuse potential of drugs like fentanyl, ultimately benefiting patients in need of these medications. By incorporating aversive agents, Nutriband's AVERSA technology could revolutionize the transdermal drug delivery landscape, offering a safer alternative for both healthcare providers and patients.
Summary
Nutriband's AVERSA technology aims to enhance the safety of transdermal drugs at risk of abuse, such as fentanyl, while ensuring patient accessibility. The company secured an $8.4 million financing round to support AVERSA Fentanyl, a patch designed to deter abuse. A long-term exclusive partnership with Kindeva Drug Delivery was also formalized to aid in bringing the product to market.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Nutriband Innovates to Enhance Safety of Transdermal Drugs with AVERSA Technology
